Heparin sensitivity and resistance: Management during cardiopulmonary bypass

Anesthesia and Analgesia

Volumn 116, Issue 6, 2013, Pages 1210-1222

  Finley, Alan ^a   Greenberg, Charles ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; HEPARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; ANTITHROMBIN III DEFICIENCY; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; DOSE RESPONSE; DRUG COST; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; LOADING DRUG DOSE; PRIORITY JOURNAL; REVIEW; PHYSIOLOGY;

ANTICOAGULANTS; ANTITHROMBINS; CARDIOPULMONARY BYPASS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; HEPARIN; HUMANS; WHOLE BLOOD COAGULATION TIME;

MLCS; MLOWN;

EID: 84878393291     PISSN: 00032999     EISSN: 15267598     Source Type: Journal    
DOI: 10.1213/ANE.0b013e31827e4e62     Document Type: Review

References (169)

1. Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008;141:757-63 (Pubitemid 351724858)
2. Hattersley PG. Activated coagulation time of whole blood. JAMA 1966;196:436-40
3. Lobato RL, Despotis GJ, Levy JH, Shore-Lesserson LJ, Carlson MO, Bennett-Guerrero E. Anticoagulation management during cardiopulmonary bypass: a survey of 54 North American institutions. J Thorac Cardiovasc Surg 2010;139:1665-6
4. Avidan MS, Levy JH, Scholz J, Delphin E, Rosseel PM, Howie MB, Gratz I, Bush CR, Skubas N, Aldea GS, Licina M, Bonfiglio LJ, Kajdasz DK, Ott E, Despotis GJ. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005;102:276-84 (Pubitemid 40189074)
5. Avidan MS, Levy JH, van Aken H, Feneck RO, Latimer RD, Ott E, Martin E, Birnbaum DE, Bonfiglio LJ, Kajdasz DK, Despotis GJ. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005;130:107-13 (Pubitemid 40941676)
6. Ranucci M, Isgrò G, Cazzaniga A, Ditta A, Boncilli A, Cotza M, Carboni G, Brozzi S. Different patterns of heparin resistance: therapeutic implications. Perfusion 2002;17:199-204 (Pubitemid 34467126)
7. Ranucci M, Isgrò G, Cazzaniga A, Soro G, Menicanti L, Frigiola A. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion 1999;14:437-42 (Pubitemid 29537489)
8. Staples MH, Dunton RF, Karlson KJ, Leonardi HK, Berger RL. Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping. Ann Thorac Surg 1994;57:1211-6 (Pubitemid 24204506)
9. Koster A, Fischer T, Gruendel M, Mappes A, Kuebler WM, Bauer M, Kuppe H. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation. J Cardiothorac Vasc Anesth 2003;17:171-5 (Pubitemid 36457470)
10. Williams MR, D'Ambra AB, Beck JR, Spanier TB, Morales DL, Helman DN, Oz MC. A randomized trial of antithrombin concentrate for treatment of heparin resistance. Ann Thorac Surg 2000;70:873-7
11. Lemmer JH Jr, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002;123:213-7 (Pubitemid 34127106)
12. Johnson EA, Mulloy B. The molecular-weight range of mucosal-heparin preparations. Carbohydr Res 1976;51:119-27
13. Lindahl U, Bäckström G, Höök M, Thunberg L, Fransson LA, Linker A. Structure of the antithrombin-binding site in heparin. Proc Natl Acad Sci USA 1979;76:3198-202
14. Rosenberg RD, Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sci USA 1979;76:1218-22 (Pubitemid 9135185)
15. Casu B, Oreste P, Torri G, Zoppetti G, Choay J, Lormeau JC, Petitou M, Sinäy P. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem J 1981;197:599-609 (Pubitemid 12232759)
16. Choay J, Petitou M, Lormeau JC, Sinaÿ P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983;116:492-9 (Pubitemid 14242772)
17. Ellis V, Scully MF, Kakkar VV. The relative molecular mass dependence of the anti-factor Xa properties of heparin. Biochem J 1986;238:329-33 (Pubitemid 16008502)
18. Oosta GM, Gardner WT, Beeler DL, Rosenberg RD. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci USA 1981;78:829-33 (Pubitemid 11159519)
19. Lindahl U, Thunberg L, Bäckström G, Riesenfeld J, Nordling K, Björk I. Extension and structural variability of the antithrombinbinding sequence in heparin. J Biol Chem 1984;259:12368-76 (Pubitemid 15204810)
20. Atha DH, Lormeau JC, Petitou M, Rosenberg RD, Choay J. Contribution of 3-O-and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. Biochemistry 1987;26:6454-61
21. Rosenberg RD, Jordan RE, Favreau LV, Lam LH. Highly active heparin species with multiple binding sites for antithrombin. Biochem Biophys Res Commun 1979;86:1319-24 (Pubitemid 9136113)
22. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K, Lansing JC, Sriranganathan N, Zhao G, Galcheva-Gargova Z, Al-Hakim A, Bailey GS, Fraser B, Roy S, Rogers-Cotrone T, Buhse L, Whary M, Fox J, Nasr M, Dal Pan GJ, Shriver Z, Langer RS, Venkataraman G, Austen KF, Woodcock J, Sasisekharan R. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358:2457-67 (Pubitemid 351793019)
23. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI; American College of Chest Physicians. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:141S-59S (Pubitemid 351892966)
24. Bray B, Lane DA, Freyssinet JM, Pejler G, Lindahl U. Antithrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin. Biochem J 1989;262:225-32 (Pubitemid 19220953)
25. Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980;255:10081-90 (Pubitemid 11214588)
26. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clotbound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-91 (Pubitemid 20271869)
27. Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982;257:2162-9 (Pubitemid 12069768)
28. Tanaka KA, Szlam F, Vinten-Johansen J, Cardin AD, Levy JH. Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan. Thromb Haemost 2005;94:808-13 (Pubitemid 41489242)
29. Conrad H, Heparin Binding Proteins. 1st ed. San Diego, CA: Academic Press, 1997
30. Peterson CB, Morgan WT, Blackburn MN. Histidine-rich glycoprotein modulation of the anticoagulant activity of heparin. Evidence for a mechanism involving competition with both antithrombin and thrombin for heparin binding. J Biol Chem 1987;262:7567-74
31. Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem 1986;261:3980-6 (Pubitemid 17198823)
32. Bârzu T, Molho P, Tobelem G, Petitou M, Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta 1985;845:196-203 (Pubitemid 15067878)
33. Preissner KT, Müller-Berghaus G. Neutralization and binding of heparin by S protein/vitronectin in the inhibition of factor Xa by antithrombin III. Involvement of an inducible heparin-binding domain of S protein/vitronectin. J Biol Chem 1987;262:12247-53 (Pubitemid 17131665)
34. Lijnen HR, Hoylaerts M, Collen D. Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma. J Biol Chem 1983;258:3803-8 (Pubitemid 13052870)
35. Sobel M, McNeill PM, Carlson PL, Kermode JC, Adelman B, Conroy R, Marques D. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991;87:1787-93
36. de Swart CA, Nijmeyer B, Roelofs JM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood 1982;60:1251-8 (Pubitemid 13211359)
37. Bjornsson TD, Wolfram KM, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther 1982;31:104-13 (Pubitemid 12135816)
38. McAvoy TJ. Pharmacokinetic modeling of heparin and its clinical implications. J Pharmacokinet Biopharm 1979;7:331-54 (Pubitemid 10246130)
39. Olsson P, Lagergren H, Ek S. The elimination from plasma of intravenous heparin. An experimental study on dogs and humans. Acta Med Scand 1963;173:619-30
40. Dyck L, Friesen RM. Do different heparin brands influence activated clotting times? J Extra Corpor Technol 1998;30:73-6 (Pubitemid 28337779)
41. Wood MK. Congenital factor XII deficiency and cardiopulmonary bypass. Ann Thorac Surg 1994;58:1565 (Pubitemid 24347577)
42. Salmenperä M, Rasi V, Mattila S. Cardiopulmonary bypass in a patient with factor XII deficiency. Anesthesiology 1991;75:539-41
43. Gerhardt MA, Greenberg CS, Slaughter TF, Stafford Smith M. Factor XII deficiency and cardiopulmonary bypass: use of a novel modification of the activated clotting time to monitor anticoagulation. Anesthesiology 1997;87:990-2 (Pubitemid 27456257)
44. Moorman RM, Reynolds DS, Comunale ME. Management of cardiopulmonary bypass in a patient with congenital factor XII deficiency. J Cardiothorac Vasc Anesth 1993;7:452-4 (Pubitemid 23231401)
45. Davidson SJ, Burman JF, Rutherford LC, Keogh BF, Yacoub MH. High molecular weight kininogen deficiency: a patient who underwent cardiac surgery. Thromb Haemost 2001;85:195-7 (Pubitemid 32140559)
46. Oram MP, Mumford AD, Morse C, Underwood S. Management of anticoagulation for coronary artery bypass surgery in a patient with severe prekallikrein deficiency. J Cardiothorac Vasc Anesth 2006;20:580-2
47. Wallock M, Arentzen C, Perkins J. Factor XII deficiency and cardiopulmonary bypass. Perfusion 1995;10:13-6
48. Conaglen PJ, Akowuah E, Theodore S, Atkinson V. Implications for cardiac surgery in patients with factor XII deficiency. Ann Thorac Surg 2010;89:625-6
49. Veronesi R, Maurelli M, Bianchi T, Toscani M, Via G, Villani MA, Pettinella S, Santambrogio LG, Fuardo M. Mitral valve repair and cardiac transplantation in a patient with factor XII deficiency. J Cardiothorac Vasc Anesth 2005;19: 419-20 (Pubitemid 40797709)
50. Burman JF, Chung HI, Lane DA, Philippou H, Adami A, Lincoln JC. Role of factor XII in thrombin generation and fibrinolysis during cardiopulmonary bypass. Lancet 1994;344:1192-3 (Pubitemid 24323709)
51. van Veen JJ, Laidlaw S, Swanevelder J, Harvey N, Watson C, Kitchen S, Makris M. Contact factor deficiencies and cardiopulmonary bypass surgery: detection of the defect and monitoring of heparin. Eur J Haematol 2009;82:208-12
52. Jones K, Nasrallah F, Darling E, Clay N, Searles B. The in vitro effects of aprotinin on twelve different ACT tests. J Extra Corpor Technol 2004;36:51-7 (Pubitemid 38392714)
53. Despotis GJ, Filos KS, Levine V, Alsoufiev A, Spitznagel E. Aprotinin prolongs activated and nonactivated whole blood clotting time and potentiates the effect of heparin in vitro. Anesth Analg 1996;82:1126-31 (Pubitemid 26157990)
54. Laurel MT, Ratnoff OD, Everson B. Inhibition of the activation of Hageman factor (factor XII) by aprotinin (Trasylol). J Lab Clin Med 1992;119:580-5
55. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 1983;33:479-94 (Pubitemid 13161964)
56. Wendel HP, Heller W, Gallimore MJ, Bantel H, Müller-Beissenhirtz H, Hoffmeister HE. The prolonged activated clotting time (ACT) with aprotinin depends on the type of activator used for measurement. Blood Coagul Fibrinolysis 1993;4:41-5 (Pubitemid 23064914)
57. Dietrich W, Jochum M. Effect of celite and kaolin on activated clotting time in the presence of aprotinin: activated clotting time is reduced by binding of aprotinin to kaolin. J Thorac Cardiovasc Surg 1995;109:177-8
58. Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite-and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study. Anesthesiology 1995;83:679-89
59. Wang JS, Lin CY, Hung WT, Karp RB. Monitoring of heparininduced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin. Anesthesiology 1992;77:1080-4 (Pubitemid 23001116)
60. Wang JS, Lin CY, Hung WT, Thisted RA, Karp RB. In vitro effects of aprotinin on activated clotting time measured with different activators. J Thorac Cardiovasc Surg 1992;104:1135-40
61. Dalbert S, Ganter MT, Furrer L, Klaghofer R, Zollinger A, Hofer CK. Effects of heparin, haemodilution and aprotinin on kaolinbased activated clotting time: in vitro comparison of two different point of care devices. Acta Anaesthesiol Scand 2006;50:461-8
62. Cohen EJ CL, Dearing JP. Activated clotting times and cardiopulmonary bypass: the effect of hemodilution and hypothermia upon activated clotting time. . J Extracorp Tech 1980;12:139-41 (Pubitemid 11177700)
63. Dietrich W, Spannagl M, Schramm W, Vogt W, Barankay A, Richter JA. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;102:505-14
64. Dietrich W, Dilthey G, Spannagl M, Richter JA. Warfarin pretreatment does not lead to increased bleeding tendency during cardiac surgery. J Cardiothorac Vasc Anesth 1995;9:250-4
65. Terai C, Saitoh D, Okamoto K, Kawakami M, Magario N. Plasma activated clotting time as an indicator of dangerous hypocoagulability in warfarin-treated trauma patients: a preliminary study. Surg Today 1998;28:834-8 (Pubitemid 28374401)
66. Chang RJ, Doherty TM, Goldberg SL. How does warfarin affect the activated coagulation time? Am Heart J 1998;136:477-9 (Pubitemid 28413546)
67. Gautam S, John RM, Stevenson WG, Jain R, Epstein LM, Tedrow U, Koplan BA, McClennen S, Michaud GF. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2011;22:248-54
68. Despotis GJ, Summerfield AL, Joist JH, Goodnough LT, Santoro SA, Spitznagel E, Cox JL, Lappas DG. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-82 (Pubitemid 24379861)
69. Kmiecik SA, Liu JL, Vaadia TS, Nichols JD, Kohtz RJ, Mills NJ, Petterson CM, Stammers AH. Quantitative evaluation of hypothermia, hyperthermia, and hemodilution on coagulation. J Extra Corpor Technol 2001;33:100-5 (Pubitemid 32466429)
70. Rani TR, Gopinath R. An unusual cause of a prolonged activated coagulation time during cardiac surgery: congenital hypofibrinogenemia. J Cardiothorac Vasc Anesth 2008;22:725-6
71. Moorehead MT, Westengard JC, Bull BS. Platelet involvement in the activated coagulation time of heparinized blood. Anesth Analg 1984;63:394-8 (Pubitemid 14172608)
72. Ammar T, Fisher CF, Sarier K, Coller BS. The effects of thrombocytopenia on the activated coagulation time. Anesth Analg 1996;83:1185-8 (Pubitemid 26418801)
73. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997;95:614-7 (Pubitemid 27063037)
74. Bode AP, Lust RM. Masking of heparin activity in the activated coagulation time (ACT) by platelet procoagulant activity. Thromb Res 1994;73:285-300 (Pubitemid 24088150)
75. Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995;75:559-62
76. Gayoso JM. 5-year incidence of thrombocytosis and the effect on heparin dose response and heparin requirements. J Extra Corpor Technol 1999;31:184-90 (Pubitemid 30176833)
77. Jervis K, Senthilnathan V, Lerner AB. Management of a patient with lupus anticoagulant and antiphospholipid syndrome for off-pump coronary artery bypass grafting using the Hepcon system. Anesth Analg 2009;108:1116-9
78. Gorki H, Malinovski V, Stanbridge RD. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg 2008;33:168-81
79. East CJ, Clements F, Mathew J, Slaughter TF. Antiphospholipid syndrome and cardiac surgery: management of anticoagulation in two patients. Anesth Analg 2000;90:1098-101 (Pubitemid 30253456)
80. Griffin MJ, Rinder HM, Smith BR, Tracey JB, Kriz NS, Li CK, Rinder CS. The effects of heparin, protamine, and heparin/protamine reversal on platelet function under conditions of arterial shear stress. Anesth Analg 2001;93:20-7 (Pubitemid 32601145)
81. Lindblad B, Wakefield TW, Whitehouse WM Jr, Stanley JC. The effect of protamine sulfate on platelet function. Scand J Thorac Cardiovasc Surg 1988;22:55-9 (Pubitemid 18087500)
82. Wakefield TW, Whitehouse WM Jr, Stanley JC. Depressed cardiovascular function and altered platelet kinetics following protamine sulfate reversal of heparin activity. J Vasc Surg 1984;1:346-55 (Pubitemid 15061417)
83. Barstad RM, Stephens RW, Hamers MJ, Sakariassen KS. Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity. Thromb Haemost 2000;83:334-7 (Pubitemid 30093241)
84. Kozek-Langenecker SA, Mohammad SF, Masaki T, Kamerath C, Cheung AK. The effects of heparin, protamine, and heparinase 1 on platelets in vitro using whole blood flow cytometry. Anesth Analg 2000;90:808-12 (Pubitemid 30190782)
85. Ni Ainle F, Preston RJ, Jenkins PV, Nel HJ, Johnson JA, Smith OP, White B, Fallon PG, O'Donnell JS. Protamine sulfate downregulates thrombin generation by inhibiting factor V activation. Blood 2009;114:1658-65
86. Khan NU, Wayne CK, Barker J, Strang T. The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph. Eur J Anaesthesiol 2010;27:624-7
87. Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998;87:781-5 (Pubitemid 28455470)
88. Welsby IJ, McDonnell E, El-Moalem H, Stafford-Smith M, Toffaletti JG. Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass. J Clin Monit Comput 2002;17:287-92 (Pubitemid 36040437)
89. Reich DL, Zahl K, Perucho MH, Thys DM. An evaluation of two activated clotting time monitors during cardiac surgery. J Clin Monit 1992;8:33-6
90. Horkay F, Martin P, Rajah SM, Walker DR. Response to heparinization in adults and children undergoing cardiac operations. Ann Thorac Surg 1992;53:822-6
91. Hug MI, Di Bernardo S, Berger F, Bauersfeld U, Weiss M. Measurement of activated clotting time in children-comparison of the Celite i-STAT ACT with the Medtronic ACT II. Acta Anaesthesiol Scand 2004;48:211-7 (Pubitemid 38166467)
92. Avendaño A, Ferguson JJ. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:907-10 (Pubitemid 24090876)
93. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975;69:685-9
94. Garvin S, FitzGerald DC, Despotis G, Shekar P, Body SC. Heparin concentration-based anticoagulation for cardiac surgery fails to reliably predict heparin bolus dose requirements. Anesth Analg 2010;111:849-55
95. Fitzgerald DJ, Patel A, Body SC, Garvin S. The relationship between heparin level and activated clotting time in the adult cardiac surgery population. Perfusion 2009;24:93-6
96. Levy JH, Montes F, Szlam F, Hillyer CD. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000;90:1076-9 (Pubitemid 30253452)
97. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg 1975;69:674-84
98. Brister SJ, Ofosu FA, Buchanan MR. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant? Thromb Haemost 1993;70:259-62 (Pubitemid 23222480)
99. Slaughter TF, LeBleu TH, Douglas JM Jr, Leslie JB, Parker JK, Greenberg CS. Characterization of prothrombin activation during cardiac surgery by hemostatic molecular markers. Anesthesiology 1994;80:520-6 (Pubitemid 24097682)
100. Garvin S, Fitzgerald D, Muehlschlegel JD, Perry TE, Fox AA, Shernan SK, Collard CD, Aranki S, Body SC. Heparin dose response is independent of preoperative antithrombin activity in patients undergoing coronary artery bypass graft surgery using low heparin concentrations. Anesth Analg 2010;111:856-61
101. Tait RC, Walker ID, Perry DJ, Islam SI, Daly ME, McCall F, Conkie JA, Carrell RW. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994;87:106-12 (Pubitemid 24207007)
102. Bucur SZ, Levy JH, Despotis GJ, Spiess BD, Hillyer CD. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 1998;38:481-98 (Pubitemid 28287507)
103. Patnaik MM, Moll S. Inherited antithrombin deficiency: a review. Haemophilia 2008;14:1229-39
104. Despotis GJ, Levine V, Joist JH, Joiner-Maier D, Spitznagel E. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation. Anesth Analg 1997;85:498-506 (Pubitemid 27381298)
105. Garvin S, Muehlschlegel JD, Perry TE, Chen J, Liu KY, Fox AA, Collard CD, Aranki SF, Shernan SK, Body SC. Postoperative activity, but not preoperative activity, of antithrombin is associated with major adverse cardiac events after coronary artery bypass graft surgery. Anesth Analg 2010;111:862-9
106. Dietrich W, Braun S, Spannagl M, Richter JA. Low preoperative antithrombin activity causes reduced response to heparin in adult but not in infant cardiac-surgical patients. Anesth Analg 2001;92:66-71 (Pubitemid 32039179)
107. Chan T, Hwang NC, Lim CH. A statistical analysis of factors predisposing patients to heparin resistance. Perfusion 2006;21:99-103
108. Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment. J Thorac Cardiovasc Surg 1983;85:346-53 (Pubitemid 13093724)
109. Bar-Yosef S, Cozart HB, Phillips-Bute B, Mathew JP, Grocott HP. Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery. Can J Anaesth 2007;54:107-13 (Pubitemid 46505507)
110. Pleym H, Videm V, Wahba A, Asberg A, Amundsen T, Bjella L, Dale O, Stenseth R. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively. Eur J Cardiothorac Surg 2006;29:933-40 (Pubitemid 43728598)
111. Matthai WH Jr, Kurnik PB, Groh WC, Untereker WJ, Siegel JE. Antithrombin activity during the period of percutaneous coronary revascularization: relation to heparin use, thrombotic complications and restenosis. J Am Coll Cardiol 1999;33:1248-56
112. Linden MD, Schneider M, Baker S, Erber WN. Decreased concentration of antithrombin after preoperative therapeutic heparin does not cause heparin resistance during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2004;18:131-5 (Pubitemid 38506855)
113. Nicholson SC, Keeling DM, Sinclair ME, Evans RD. Heparin pretreatment does not alter heparin requirements during cardiopulmonary bypass. Br J Anaesth 2001;87:844-7 (Pubitemid 33130273)
114. Shore-Lesserson L, Manspeizer HE, Bolastig M, Harrington D, Vela-Cantos F, DePerio M. Anticoagulation for cardiac surgery in patients receiving preoperative heparin: use of the highdose thrombin time. Anesth Analg 2000;90:813-8 (Pubitemid 30190783)
115. Raya-Sánchez JM, González-Reimers E, Rodríguez- Martín JM, Santolaria-Fernández F, Molina-Pérez M, Rodríguez-Moreno F, Martínez-Riera A. Coagulation inhibitors in alcoholic liver cirrhosis. Alcohol 1998;15:19-23
116. Damus PS, Wallace GA. Immunologic measurement of antithrombin III-heparin cofactor and alpha2 macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy. Thromb Res 1975;6:27-38
117. Segal H, Cottam S, Potter D, Hunt BJ. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology 1997;25:683-8 (Pubitemid 27106454)
118. Kauffmann RH, Veltkamp JJ, Van Tilburg NH, Van Es LA. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 1978;65:607-13 (Pubitemid 9054939)
119. Chen TY, Huang CC, Tsao CJ. Hemostatic molecular markers in nephrotic syndrome. Am J Hematol 1993;44:276-9
120. Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998;24:19-25 (Pubitemid 28126219)
121. Legnani C, Preda L, Palareti G, Lunghi B, Rossi E, Coccheri S. Reduced inhibition of activated prothrombin by heparin and venous thromboembolism: heparin resistance revisited. Haematologica 2002;87:182-8 (Pubitemid 34160625)
122. Na S, Shim JK, Chun DH, Kim DH, Hong SW, Kwak YL. Stabilized infective endocarditis and altered heparin responsiveness during cardiopulmonary bypass. World J Surg 2009;33:1862-7
123. Niebler RA, Christensen M, Berens R, Wellner H, Mikhailov T, Tweddell JS. Antithrombin replacement during extracorporeal membrane oxygenation. Artif Organs 2011;35:1024-8
124. Stiller B, Lemmer J, Merkle F, Alexi-Meskishvili V, Weng Y, Hübler M, Koster A, Drews T, Lange PE, Hetzer R. Consumption of blood products during mechanical circulatory support in children: comparison between ECMO and a pulsatile ventricular assist device. Intensive Care Med 2004;30:1814-20 (Pubitemid 39297187)
125. Becker RC, Corrao JM, Bovill EG, Gore JM, Baker SP, Miller ML, Lucas FV, Alpert JA. Intravenous nitroglycerin-induced heparin resistance: a qualitative antithrombin III abnormality. Am Heart J 1990;119:1254-61 (Pubitemid 20215608)
126. Brack MJ, More RS, Hubner PJ, Gershlick AH. The effect of low dose nitroglycerin on plasma heparin concentrations and activated partial thromboplastin times. Blood Coagul Fibrinolysis 1993;4:183-6 (Pubitemid 23064939)
127. Habbab MA, Haft JI. Heparin resistance induced by intravenous nitroglycerin. A word of caution when both drugs are used concomitantly. Arch Intern Med 1987;147:857-60 (Pubitemid 17089733)
128. Gonzalez ER, Jones HD, Graham S, Elswick RK. Assessment of the drug interaction between intravenous nitroglycerin and heparin. Ann Pharmacother 1992;26:1512-4
129. Schoenenberger RA, Ménat L, Weiss P, Marbet GA, Ritz R. Absence of nitroglycerin-induced heparin resistance in healthy volunteers. Eur Heart J 1992;13:411-4
130. Berk SI, Grunwald A, Pal S, Bodenheimer MM. Effect of intravenous nitroglycerin on heparin dosage requirements in coronary artery disease. Am J Cardiol 1993;72:393-6 (Pubitemid 23238420)
131. Lepor NE, Amin DK, Berberian L, Shah PK. Does nitroglycerin induce heparin resistance? Clin Cardiol 1989;12:432-4 (Pubitemid 19201457)
132. Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am 2004;33:431-53 (Pubitemid 38680638)
133. Franz IW, Van Der Meyden J, Tönnesmann U, Müller JF, Röcker L, Hopfenmüller W. [Blood coagulation in normotensives and hypertensives in relation to their body mass index]. Dtsch Med Wochenschr 2002;127:2374-8 (Pubitemid 35351784)
134. Wattanakit K, Folsom AR, Selvin E, Weatherley BD, Pankow JS, Brancati FL, Hirsch AT. Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 2005; 180:389-97 (Pubitemid 41072911)
135. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1997;96:1102-8 (Pubitemid 27344210)
136. Uprichard J, Manning RA, Laffan MA. Monitoring heparin anticoagulation in the acute phase response. Br J Haematol 2010;149:613-9
137. Kumano N, Ikeda S, Arimori Y, Ono T, Saeki S. [Heparin resistance associated with elevated factor VIII]. Masui 2008;57:471-3 (Pubitemid 351599878)
138. Raschke RA, Guidry JR, Foley MR. Apparent heparin resistance from elevated factor VIII during pregnancy. Obstet Gynecol 2000;96:804-6
139. Ellis RJ, Cunningham MT, Cook JD. Laboratory heparin resistance in burn injury complicated by venous thrombosis. Burns 1999;25:749-52
140. Cirisano FD, Lee S, Greenspoon JS. Apparent heparin resistance form elevated factor VIII in a patient with postoperative deep venous thrombosis. A case report. J Reprod Med 1996;41:191-4 (Pubitemid 26087668)
141. Edson JR, Krivit W, White JG. Kaolin partial thromboplastin time: high levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants. J Lab Clin Med 1967;70:463-70
142. Conard J, Lecompte T, Horellou MH, Cazenave B, Samama M. Antithrombin III in patients treated with subcutaneous or intravenous heparin. Thromb Res 1981;22:507-11 (Pubitemid 11035626)
143. Heller EL, Paul L. Anticoagulation management in a patient with an acquired antithrombin III deficiency. J Extra Corpor Technol 2001;33:245-8 (Pubitemid 34142995)
144. Gravlee GP, Haddon WS, Rothberger HK, Mills SA, Rogers AT, Bean VE, Buss DH, Prough DS, Cordell AR. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg 1990;99:518-27 (Pubitemid 20097779)
145. Gravlee GP, Rogers AT, Dudas LM, Taylor R, Roy RC, Case LD, Triscott M, Brown CW, Mark LJ, Cordell AR. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology 1992;76:393-401
146. Sabbagh AH, Chung GK, Shuttleworth P, Applegate BJ, Gabrhel W. Fresh frozen plasma: a solution to heparin resistance during cardiopulmonary bypass. Ann Thorac Surg 1984;37:466-8 (Pubitemid 14077464)
147. Mintz PD, Blatt PM, Kuhns WJ, Roberts HR. Antithrombin III in fresh frozen plasma, cryoprecipitate, and cryoprecipitatedepleted plasma. Transfusion 1979;19:597-8 (Pubitemid 10178358)
148. Barnette RE, Shupak RC, Pontius J, Rao AK. In vitro effect of fresh frozen plasma on the activated coagulation time in patients undergoing cardiopulmonary bypass. Anesth Analg 1988;67:57-60
149. Leong CK, Ong BC. A case report of heparin resistance due to acquired antithrombin III deficiency. Ann Acad Med Singap 1998;27:877-9 (Pubitemid 29102357)
150. Despotis GJ, Levine V, Alsoufiev A, Joist H, Goodnough LT, Pasque M. Recurrent thrombosis of biventricular-support devices associated with accelerated intravascular coagulation and increased heparin requirements. J Thorac Cardiovasc Surg 1996;112:538-40 (Pubitemid 26301868)
151. Soloway HB, Christiansen TW. Heparin anticoagulation during cardiopulmonary bypass in an antithrombin-III deficient patient. Implications relative to the etiology of heparin rebound. Am J Clin Pathol 1980;73:723-5 (Pubitemid 10047215)
152. Spiess BD. Treating heparin resistance with antithrombin or fresh frozen plasma. Ann Thorac Surg 2008;85:2153-60 (Pubitemid 351685591)
153. Edmunds T, Van Patten SM, Pollock J, Hanson E, Bernasconi R, Higgins E, Manavalan P, Ziomek C, Meade H, McPherson JM, Cole ES. Transgenically produced human antithrombin: structural and functional comparison to human plasmaderived antithrombin. Blood 1998;91:4561-71 (Pubitemid 28270304)
154. Kanbak M. The treatment of heparin resistance with Antithrombin III in cardiac surgery. Can J Anaesth 1999;46:581-5 (Pubitemid 29327686)
155. Van Norman GA, Gernsheimer T, Chandler WL, Cochran RP, Spiess BD. Indicators of fibrinolysis during cardiopulmonary bypass after exogenous antithrombin-III administration for acquired antithrombin III deficiency. J Cardiothorac Vasc Anesth 1997;11:760-3 (Pubitemid 27408675)
156. Conley JC, Plunkett PF. Antithrombin III in cardiac surgery: an outcome study. J Extra Corpor Technol 1998;30:178-83 (Pubitemid 29152673)
157. Levy JH, Despotis GJ, Szlam F, Olson P, Meeker D, Weisinger A. Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study. Anesthesiology 2002;96:1095-102 (Pubitemid 34462569)
158. Slaughter TF, Mark JB, El-Moalem H, Hayward KA, Hilton AK, Hodgins LP, Greenberg CS. Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation. Blood Coagul Fibrinolysis 2001;12:25-31 (Pubitemid 32150248)
159. Babka R, Colby C, El-Etr A, Pifarré R. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery. J Thorac Cardiovasc Surg 1977;73:780-2 (Pubitemid 8088441)
160. Verska JJ. Control of heparinization by activated clotting time during bypass with improved postoperative hemostasis. Ann Thorac Surg 1977;24:170-3 (Pubitemid 8163321)
161. Akl BF, Vargas GM, Neal J, Robillard J, Kelly P. Clinical experience with the activated clotting time for the control of heparin and protamine therapy during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1980;79:97-102 (Pubitemid 10215466)
162. Jumean HG, Sudah F. Monitoring of anticoagulant therapy during open-heart surgery in children with congenital heart disease. Acta Haematol 1983;70:392-5 (Pubitemid 14248250)
163. Lefemine AA, Lewis M. Activated clotting time for control of anticoagulation during surgery. Am Surg 1985;51:274-8 (Pubitemid 15041255)
164. Metz S, Keats AS. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding. Ann Thorac Surg 1990;49:440-4 (Pubitemid 20097039)
165. Niinikoski J, Laato M, Laaksonen V, Jalonen J, Inberg MV. Use of activated clotting time to monitor anticoagulation during cardiac surgery. Scand J Thorac Cardiovasc Surg 1984;18:57-61 (Pubitemid 14131649)
166. Papaconstantinou C, Rådegran K. Use of the activated coagulation time in cardiac surgery. Effects on heparin-protamine dosages and bleeding. Scand J Thorac Cardiovasc Surg 1981;15:213-5 (Pubitemid 11063703)
167. Preiss DU, Schmidt-Bleibtreu H, Berguson P, Metz G. Blood transfusion requirements in coronary artery surgery with and without the activated clotting time (ACT) technique. Klin Wochenschr 1985;63:252-6 (Pubitemid 15143582)
168. Roth JA, Cukingnan RA, Scott CR. Use of activated coagulation time to monitor heparin during cardiac surgery. Ann Thorac Surg 1979;28:69-72 (Pubitemid 9223767)
169. Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, Song HK, Clough ER, Shore-Lesserson LJ, Goodnough LT, Mazer CD, Shander A, Stafford-Smith M, Waters J, Baker RA, Dickinson TA, FitzGerald DJ, Likosky DS, Shann KG. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011;91:944-82